SRP0146

Sigma-Aldrich

PRMT5/MEP50 Active human

recombinant, expressed in baculovirus infected insect cells, ≥70% (SDS-PAGE)

Sinónimos:
HMT1 hnRNP methyltransferase-like 5(HRMT1L5), shk1 kinase-binding protein 1 homolog (SKB1), Jak-binding protein 1 (JBP1), ICln-binding protein (IBP72) 72 kDa, Arginine methyltransferase 5
NACRES:
NA.32
En este momento no podemos mostrarle ni los precios ni la disponibilidad

biological source

human

recombinant

expressed in baculovirus infected insect cells

assay

≥70% (SDS-PAGE)

form

aqueous solution

mol wt

73 kDa

packaging

pkg of 20 μg

storage condition

avoid repeated freeze/thaw cycles

concentration

>0.02 mg/mL

NCBI accession no.

UniProt accession no.

shipped in

dry ice

storage temp.

−70°C

Gene Information

human ... PRMT5(10419)

General description

Protein arginine methyltransferase 5 (PRMT5) also referred to as Janus kinase-binding protein 1, is encoded by the gene mapped to human chromosome 14q11.2. PRMT5 enzyme, containing 637 amino acids, belongs to type II enzymes, which is a subclass of PRMT family. PRMT5 is predominantly expressed at distinct level in various organs including heart, muscle and testis.
Human PRMT5 (GenBank Accession No. NM_006109), amino acids 2-end, with N-terminal DDDDK tag (FLAG), MW = 73kDa, expressed in a Baculovirus infected Sf9 cell expression system.

Application

Useful for the study of enzyme kinetics, screening inhibitors, and selectivity profiling.

Biochem/physiol Actions

Protein arginine methyltransferase 5 (PRMT5) catalyzes the symmetric dimethylation of arginine residues. It is implicated in various biological functions such as ribosome biogenesis, assembly of the Golgi apparatus, cellular differentiation, cellular proliferation, apoptosis, and germ cell specification. Irregular expression of PRMT5 leads to several type of cancers such as leukemia and lymphoma, gastric cancer, breast cancer and colorectal cancer. PRMT5 plays an important role in the regulation of cell growth, proliferation and apoptosis in epithelial ovarian cancer cell lines A2780 and SKOV3. PRMT5 enables nuclear factor-κB (NF-κB) activation via demethylating arginine 30 (R30) on the p65 subunit of NF-κB. PRMT5 participates in transcriptional regulation by methylating histones H2A, H3R8, and H4R3 as well as by inhibiting the expression of suppressor of tumorigenicity 7 (ST7), and nonmetastatic 23 (NM23) genes. PRMT5 enhances DNA damage response via methylation of tumor suppressor p53 on R333, R335, and R337 in the oligomerization domain.

Unit Definition

One unit is defined as the amount of enzyme required to methylate 1 pmol of substrate/min at 37°C.

Physical form

Formulated in 25 mM Tris-HCl, pH 8.0, 100 mM NaCl, 0.05% Tween-20, 10% glycerol and 3 mM DTT.

Preparation Note

Thaw on ice. Upon first thaw, briefly spin tube containing enzyme to recover full content of the tube. Aliquot enzyme into single use aliquots. Store remaining undiluted enzyme in aliquots at -70°C. Note: Enzyme is very sensitive to freeze/thaw cycles.

RIDADR

NONH for all modes of transport

WGK Germany

WGK 1

Flash Point F

Not applicable

Flash Point C

Not applicable

Certificado de Análisis
PRMT5 dimethylates R30 of the p65 subunit to activate NF-?B.
Wei H
Proceedings of the National Academy of Sciences of the USA, 110(33), 13516-13521 (2013)
Overexpression of PRMT5 promotes tumor cell growth and is associated with poor disease prognosis in epithelial ovarian cancer.
Bao X
The Journal of Histochemistry and Cytochemistry, 61(3), 206-217 (2013)

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico

Redes sociales

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

Merck

Investigación. Desarrollo. Producción.

Somos un proveedor líder para la industria de Ciencias de la Vida con soluciones y servicios para investigación, desarrollo y producción biotecnológicos, y para desarrollo y producción de tratamientos farmacéuticos

© 2021 Merck KGaA, Darmstadt, Alemania y/o sus filiales. Todos los derechos reservados.

Queda estrictamente prohibida la reproducción sin permiso de cualquiera de los materiales de la página web.